Geoffrey von Maltzahn is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies in healthcare, nutrition, and agriculture. Geoffrey has co-founded companies that have, in aggregate, achieved over $5 billion in public and private market capitalization. Through his role in Flagship Pioneering, these include Kaleido Biosciences, Indigo Agriculture, SeresTherapeutics, and Axcella Health which are, respectively, pioneering novel chemistries to drive the human microbiome; plant microbiome products for crop improvement; the first microbiome therapeutics; and amino acid-based drugs.

Geoffrey is an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed publications. Geoffrey has received a number of awards and honors, including: Business Insider’s 30 Biotech Leaders Under 40; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative student at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; the Harvard-MIT Martha Gray Prize; and the Randolph G. Wei Award, which is awarded for MIT’s most outstanding contribution at the interface of life sciences and engineering undergraduate research. Geoffrey and his inventions have been profiled by Forbes, the Economist, CNN, Scientific American, Popular Sciences, MIT Technology Review, and many others.

Geoffrey earned a Ph.D. in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, M.D., Ph.D.; a M.S. in bioengineering from the University of California, San Diego; and a S.B. in chemical engineering from MIT.